EASTMAN KODAK CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EASTMAN KODAK CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $414.00M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $379.00M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $381.00M | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $357.00M | Mar 15, 2018 |
| FY2016 | Dec 31, 2016 | $404.00M | Mar 7, 2017 |
| FY2016 | Sep 30, 2016 | $380.00M | Mar 7, 2017 |
| FY2016 | Jun 30, 2016 | $397.00M | Mar 7, 2017 |
| FY2016 | Mar 31, 2016 | $362.00M | Mar 7, 2017 |
| FY2016 | Dec 31, 2015 | $439.00M | Mar 7, 2017 |
| FY2016 | Sep 30, 2015 | $425.00M | Mar 7, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.12B | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.21B | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $1.15B | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $1.03B | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.24B | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | $1.32B | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.39B | Apr 1, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.53B | Mar 15, 2018 |
| FY2016 | Dec 31, 2016 | $1.54B | Mar 7, 2017 |
| FY2016 | Dec 31, 2015 | $1.71B | Mar 7, 2017 |
| FY2016 | Dec 31, 2014 | $2.05B | Mar 7, 2017 |
| FY2012 | Dec 31, 2012 | $4.11B | Mar 11, 2013 |
| FY2011 | Dec 31, 2011 | $6.02B | Feb 29, 2012 |
| FY2011 | Dec 31, 2010 | $1.94B | Feb 29, 2012 |
| FY2011 | Sep 30, 2010 | $1.76B | Feb 29, 2012 |
| FY2011 | Jun 30, 2010 | $1.56B | Feb 29, 2012 |
| FY2011 | Mar 31, 2010 | $1.91B | Feb 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $203.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $210.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $170.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $164.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $135.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $182.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | $180.00M | Mar 17, 2020 |
| FY2017 | Dec 31, 2017 | $94.00M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $87.00M | Mar 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($128.00M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $102.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $75.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $26.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $24.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($541.00M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $116.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | ($16.00M) | Mar 17, 2020 |
| FY2017 | Dec 31, 2017 | $129.00M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | ($46.00M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($7.00M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $4.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($26.00M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($46.00M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($74.00M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($102.00M) | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | ($118.00M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($207.00M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $113.00M | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $33.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $34.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $34.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $33.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $34.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $42.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | $48.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $64.00M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $60.00M | Mar 15, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $179.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $159.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $153.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $177.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $172.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $211.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | $224.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $239.00M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $198.00M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($7.00M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $38.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($116.00M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($47.00M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($35.00M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $12.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | ($62.00M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($67.00M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($15.00M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $56.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $32.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $31.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $21.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $17.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $15.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | $33.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $38.00M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $41.00M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.62B | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.00B | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.36B | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $2.29B | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $2.17B | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.25B | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.42B | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.51B | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.71B | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.78B | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $904.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.21B | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.04B | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.19B | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $980.00M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.13B | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.34B | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.49B | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.69B | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $614.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $641.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $931.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $1.04B | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $781.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $77.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2019 | $99.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2018 | ($3.00M) | Mar 15, 2022 |
| FY2019 | Dec 31, 2017 | $57.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | ($73.00M) | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $12.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $12.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $12.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $12.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $12.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $12.00M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $12.00M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $12.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | $68.00M | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($521.00M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($393.00M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($495.00M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($570.00M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($596.00M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($620.00M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($79.00M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($200.00M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($174.00M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($268.00M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $337.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $201.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $255.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $217.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $362.00M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $196.00M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $233.00M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $233.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $343.00M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $434.00M | Mar 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $467.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $458.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $317.00M | Mar 14, 2024 |
| FY2015 | Dec 31, 2015 | $680.00M | Apr 1, 2016 |
| FY2014 | Dec 31, 2014 | $677.00M | Mar 16, 2015 |
| FY2013 | Dec 31, 2013 | $678.00M | Mar 19, 2014 |
| FY2012 | Dec 31, 2012 | $2.12B | Mar 11, 2013 |
| FY2012 | Dec 31, 2011 | $1.52B | Mar 11, 2013 |
| FY2011 | Dec 31, 2010 | $1.25B | Feb 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | (9) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Mar 15, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | 2 | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | (1) | Mar 15, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | (9) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Mar 15, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | 2 | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | (1) | Mar 15, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 97.40M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 80.50M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 79.60M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 79.10M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 78.70M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 77.20M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 43.20M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 42.80M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 42.60M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 42.40M | Mar 15, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $0 | Feb 25, 2011 |
| FY2010 | Dec 31, 2009 | $0 | Feb 25, 2011 |
| FY2010 | Dec 31, 2008 | $139.00M | Feb 25, 2011 |